James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

Visit https://www.peervoice.com/DSN860 to view the entire programme with slides. After completing “James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis”, participants will be able to: Explain how the immunological processes underpinning the pathophysiology of generalised myasthenia gravis (gMG) are targeted by the novel mechanisms of action of emerging therapies; Discuss key characteristics of currently available targeted therapies for gMG with particular reference to potential benefits and limitations; and Evaluate how specific patient factors can impact individualised treatment plans.